Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0835 • ACR Convergence 2024
Effective Engineering of CD8+ T Cells from Autoimmune Disease Patients Utilizing a CD8-Targeted Lipid NanoparticleEncoding an Anti-CD19 CAR mRNA(CPTX2309)
Yan Zhang¹, Brittany Ross¹, Diana Galvan¹, Yanjie Bao¹, Daiki Matsuda¹, Shaun Grosskurth¹, Iago Pinal-Fernandez², Maria Casal-Dominguez³, Gregor Adams¹, Michael Rosenzweig¹, Ramin Farzaneh-Far¹, Priya Karmali¹, Adrian Bot¹, Andrew Mammen² and Haig Aghajanian¹, ¹Capstan Therapeutics, San Diego, CA, ²NIH, Bethesda, MD, ³NIH, Bathesda, MD
Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating durable clinical efficacy in various autoimmune disease (AID)…
Abstract Number: 1006 • ACR Convergence 2024
Associations Between Rheumatic Diseases and Mental Health Disorders
Thoai Vu, Sivam Bhatt and Janet Lewis, University of Virginia, Charlottesville, VA
Background/Purpose: Rheumatic diseases are frequently linked to a reduced quality of life (QoL), particularly as disease severity escalates. Patients with rheumatic conditions often exhibit high…
Abstract Number: 1253 • ACR Convergence 2024
Patterns of Patient-reported Outcome Measures in Patients with Systemic Lupus Erythematosus with or Without Concurrent Fibromyalgia
Heather Gold¹, Yi Li¹, Rebecca Anthopolos¹, Peter Izmirly², Jill Buyon¹, Mala Masson³, Brooke Cohen¹, Kamil Barbour⁴, Amit Saxena⁵, H Michael Belmont⁵, Chung-E Tseng⁶ and Kelly Corbitt⁷, ¹NYU Grossman School of Medicine, New York, NY, ²New York University Grossman School of Medicine, New York, NY, ³NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁴CDC, Alpharetta, GA, ⁵NYU School of Medicine, New York, NY, ⁶NYU Langone Health, Flushing, NY, ⁷University of Miami Miller School of Medicine, El Portal, FL
Background/Purpose: Patients with SLE often have concomitant FM or symptoms similar to FM, including chronic pain, fatigue, sleep disturbance, and/or depression, potentially distinct from immune-mediated…
Abstract Number: 1280 • ACR Convergence 2024
Abnormal Cortical Gyrification Patterns in Adolescents with Childhood-onset SLE: Early Associations with Perceived Fatigue
Diana Valdes Cabrera¹, Tala El Tal², Santiago Arciniegas¹, Oscar Mwizerwa³, Asha Jeyanathan³, Lawrence Ng¹, Paris Moaf¹, Joanna Law⁴, Sarah Mossad⁵, Birgit Ertl-Wagner¹, Ann Yeh¹, Helen Branson¹, Adrienne Davis⁶, Linda Hiraki¹, Deborah Levy¹, Busi Zapparoli⁷, Ashley Danguecan⁸ and Andrea Knight⁹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital For Sick Children & Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁵Hospital for Sick Children, Toronto, ON, Canada, ⁶Division of Pediatric Emergency Medicine, Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Etobicoke, ON, Canada, ⁸The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ⁹Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Fatigue and brain fog are early complaints in adolescents with childhood-onset SLE (cSLE), who experience disease onset during a critical period of brain development.…
Abstract Number: 1495 • ACR Convergence 2024
Real-World Reduction in Disease Flares and Oral Corticosteroid Use with Anifrolumab Therapy in Systemic Lupus Erythematosus: A Claims-Based Study
Mawuena Binka¹, Rana Muhammad Qasim Khan², Joseph Tkacz³, Donna McMorrow³, Laurence Gozalo³ and Gail Kerr⁴, ¹BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ²BioPharmaceuticals Medical, AstraZeneca, Wilmington, ³Inovalon, Bowie, MD, ⁴Veterans Affairs Medical Center, Georgetown and Howard University Hospitals, Washington, DC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, chronic autoimmune disease characterized by frequent episodes of disease activity (flares) of varying severity.1 SLE flares are…
Abstract Number: 1511 • ACR Convergence 2024
Lupus Nephritis and Response to Treatment in Latin America
Rosana Quintana¹, Romina Nieto², Diana Carolina Fernández Ávila³, Rosa Serrano Morales⁴, Guillermina Harvey⁵, Lucia Hernandez⁶, Karen Roberts⁷, Marina Scolnik⁸, Carmen Funes Soaje⁹, Paula Alba¹⁰, Veronica Saurit¹¹, Mercedes Garcia¹², Guillermo Berbotto¹³, VERONICA BELLOMIO¹⁴, Wilfredo Patiño Grageda¹⁵, Graciela Gómez¹⁶, Cecilia Pisoni¹⁷, Ana Malvar¹⁸, Vicente Juarez¹⁹, Nilzio A. Da Silva²⁰, ODIRLEI MONTICIELO²¹, Henrique Ataide Mariz²², Francinne Machado Ribeiro²³, Eduardo Borba²⁴, Luciana Parente²⁴, Edgard Torres²⁵, Oscar Neira²⁶, Loreto Massardo²⁷, Gustavo Aroca Martínez²⁸, Carlos A. Cañas Davila²⁹, Gerardo Quintana López³⁰, Carlos Enrique Toro-Gutierrez³¹, Mario Moreno³², Andres Zuñiga³³, Miguel Angel Saavedra Salinas³⁴, Margarita Portela Hernandez³⁵, Hilda Fragoso-Loyo³⁶, Luis H. Silveira Torre³⁷, Ignacio García De La Torre³⁸, Carlos Abud Mendoza³⁹, Marcos Fonseca Hernández⁴⁰, Jorge Esquivel-Valerio⁴¹, Isabel Acosta Colman⁴², Jhonatan Losanto⁴³, Claudia Selene Mora Trujillo⁴⁴, Katiuzka Zuñiga Corrales⁴⁵, Roberto Muñoz Louis⁴⁶, Martin Rebella⁴⁷, Álvaro Danza⁴⁸ Manuel Ugarte-Gil⁴⁹, Graciela Alarcon⁵⁰, Urbano Sbarigia⁵¹, Federico Zazzetti⁵², Ashley Orillion⁵³, Guillermo Pons-Estel⁵⁴ and Bernardo Pons-Estel⁵⁴, ¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, ³Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, ⁴Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, ⁵Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina, Rosario, Argentina, ⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, ⁷Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁹Hospital Italiano, Cordoba, Argentina, ¹⁰Hospital Cordoba, Cordoba, Spain, ¹¹hospital privado universitario de cordoba, Córdoba, Argentina, ¹²HIGA San Martin, La Plata, Argentina, ¹³Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, ROSARIO, Argentina, ¹⁴Hospital Padilla, San Miguel de Tucumán, Argentina, ¹⁵Hospital General de Agudos Dr Ramos Mejia, CABA, Argentina, ¹⁶Instituto de Investigaciones Médicas Alfredo Lanari, Autónoma de Buenos Aires, Argentina, ¹⁷CEMIC, Buenos Aires, Argentina, ¹⁸Organización Médica de Investigación, Buenos Aires, Argentina, ¹⁹Hospital Señor del Milagro, Salta, Salta, Argentina, ²⁰Hospital das Clinicas, Universidad Federal de Goias, Goias, Goias, Brazil, ²¹HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, ²²Universidad Federal de Pernambuco, Pernambuco, Brazil, ²³Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, ²⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²⁵Universidad Federal São Paulo, São Paulo, SP, Brazil, ²⁶Hospital del Salvador, Santiago de Chile, Chile, ²⁷Facultad de Medicina y Ciencia, Universidad San Sebastián, San Sebastián, Chile, ²⁸Universidad Simón Bolivar, Barranquilla, Colombia, Barranquilla, Colombia, ²⁹Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, ³⁰Universidad de Los Andes, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia, ³¹Reference Center for Osteoporosis & Rheumatology, Cali, Colombia, ³²Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, Guayaquil, Ecuador, ³³Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, ³⁴División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, ³⁵Departamento de Reumatología del Hospital de especialidades del Centro Médico Nacional Siglo XXI del Instituto Mexicano del Seguro Social (IMSS), Mexico, Mexico, ³⁶Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ³⁷Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, ³⁸Depto. de Inmunología y Reumatología; Centro de Estudios de Investigación Básica y Clínica, Guadalajara, Mexico, ³⁹Hospital Central Dr. Ignacio Morones Prieto, SLP, México, SLP, Mexico, ⁴⁰Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí, Mexico, ⁴¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, ⁴²Hospital de Clínicas I, Asunción, Paraguay, ⁴³Hospital de Clínicas I, San Lorenzo, Paraguay, ⁴⁴Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ⁴⁵Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, ⁴⁶Hospital Docente Padre Billini, Santo Domingo, República Dominicana, Santo Domingo, Dominican Republic, ⁴⁷Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, ⁴⁸Médica Uruguaya Corporación de Asistencia Médica (MUCAM). Clínica Médica - Facultad de Medicina - UdelaR, Montevideo, Uruguay, ⁴⁹Universidad Cientifica del Sur, Lima, Lima, Peru, ⁵⁰The University of Alabama at Birmingham, Birmingham, AL, ⁵¹Johnson & Johnson Innovative Medicine, Brussels, Belgium, ⁵²Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵³Johnson & Johnson Innovative Medicine, Spring House, PA, PA, ⁵⁴Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina
Background/Purpose: The Latin American Group for the Study of Lupus (GLADEL) 2.0 is an observational prevalent and incident cohort of patients with systemic lupus erythematosus…
Abstract Number: 1528 • ACR Convergence 2024
Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: National Inpatient Sample Analysis
Maria Romero Noboa¹, Almurtada Razok², Husam El Sharu³ and Rafaella Litvin², ¹University of Alabama at Birmingham, Chicago, IL, ²John H Stroger Jr Hospital of Cook County, Chicago, IL, ³East Carolina University, Greenville, NC
Background/Purpose: Systemic Lupus Erythematosus (SLE) can lead to a range of pulmonary complications, including Pulmonary Arterial Hypertension (PAH), which affects between 0.5% and 17.5% of…
Abstract Number: 1548 • ACR Convergence 2024
Anifrolumab in Systemic Lupus Erythematosus. Spanish National Registry in a Real-world Setting
Carmen Secada Gómez¹, Vanesa Calvo-Rio², Miriam Retuerto Guerrero³, Judit Font⁴, Ivette Casafont-Sole⁵, Adrián Mayo-Juanatey⁶, Juan José Alegre Sancho⁶, Dalifer Freites Nuñez⁷, Cristina Hormigos⁸, Noemí Garrido-Puñal⁹, GUILLERMO GONZALEZ ARRIBAS¹⁰, Andrea García-Valle¹¹, Juan Roberto Miguelez Sanchez¹², Marta Ibáñez Martínez¹³, Fernando Lozano Morillo¹⁴, Ángel García Manzanares¹⁵, Sebastián Sandoval-Moreno¹⁶, Josefina Cortés-Hernández¹⁷, Desiree Palma¹⁸, Leticia Lojo Oliveira¹⁹, EVELIN CERVANTES PEREZ²⁰, PAZ COLLADO²¹, Cristina Arciniega Larios²², Luis Sala Icardo²³, Eztizen Labrador-Sánchez²⁴, Cilia Peralta Ginés²⁵, Nahia Plaza-Aulestia²⁶, Miguel Medina Malone²⁷, José Rosas-Gómez de Salazar²⁸, Montserrat Corteguera²⁹, Laura Cebrián¹⁹, Fred Anton Pages³⁰, JOSE RAMON LAMUA RIAZUELO³¹, maria Dolores Fábregas canales³², María José Alados Hernández³³, Marta Garijo Bufort³⁴, Anna Pamies Corts³⁵, Luis Sarabia De Ardanaz³⁶, Rodrigo Aguirre-del-Pino³⁷, José Ángel Cabezas Lefler³⁸, Álvaro Seijas-Lopez³⁷, Carmen Carrasco-Cubero³⁹, Ana López-Cerón Cofiño⁴⁰, Vera Ortiz-Santamaria⁴¹, Santos Castañeda⁴², María Laiño Piñeiro⁴³, Carmen Ordás Calvo⁴⁴, Celia Arconada Lopez⁴⁵, Carmen Bejerano⁴⁶ and Ricardo Blanco-Alonso⁴⁷, ANA URRUTICOECHEA⁴⁸, Blanca Garcia-Magallon⁴⁹, Ana Valeria Acosta Alfaro⁵⁰, Samuel Leal Rodriguez⁵¹, Marina Salido Olivares⁵² and Patricia Lavilla⁵³ ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Valdecilla Hospital, Santander, Cantabria, Spain, ³Complejo Asistencial Universitario de León, Leon, Spain, ⁴Hospital Germans Trias i Pujol, Barcelona, Spain, ⁵Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁶Hospital Universitario Doctor Peset, Valencia, Spain, ⁷Hospital Clínico San Carlos. Madrid. Spain., Madrid, Spain, ⁸Hospital Clínico San Carlos, Madrid, Madrid, Spain, ⁹Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹⁰Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹¹Hospital General Río Carrión, Palencia, Spain, ¹²Hospital Universitario de Móstoles, Madrid, Spain, ¹³Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ¹⁴Hospital Central de La Defensa Gómez Ulla, Madrid, Spain, ¹⁵Hospital Universitario de Torrevieja, Alicante, Spain, ¹⁶Hospital Universitario Vall d´Hebrón, Barcelona, Spain, ¹⁷Hospital Universitario Vall d´Hebrón Hospitals, Barcelona, ES, Barcelona, Spain, ¹⁸Hospital Rafael Méndez, Lorca, Murcia, Spain, ¹⁹Hospital Universitario Infanta Leonor, Madrid, Spain, ²⁰Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Galicia, Spain, ²¹Hospital Universitario Severo Ochoa, MADRID, Spain, ²²Hospital de Mérida, Badajoz, Spain, ²³Hospital Universitario de Torrejón, Madrid, Spain, ²⁴Hospital General de La Rioja, Logroño, Spain, ²⁵Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ²⁶Hospital Galdakao, Vizcaya, Spain, ²⁷Hospital Calahorra, La Rioja, Spain, ²⁸Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, ²⁹ComplejoAsistencial de Ávila, Ávila, Spain, ³⁰Complejo Asistencial De Segovia, Segovia, Spain, ³¹Hospital Universitario del Henares, Madrid, Spain, ³²Hospital de Barbastro, Huesca, Spain, ³³Hospital Universitario Puerta del Mar, Cádiz, Spain, ³⁴Hospital de Sagunto, Valencia, Spain, ³⁵Hospital Verge de la Cinta, Tortosa, TARRAGONA, Spain, ³⁶Complejo Hospitalario de Jaén, Jaén, Spain, ³⁷Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁸Complejo Asistencial de Zamora, Zamora, Spain, ³⁹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ⁴⁰Hospital Santa Bárbara, Soria, Spain, ⁴¹Hospital General de Granollers, Barcelona, Spain, ⁴²Hospital Universitario de la Princesa, Madrid, Spain, ⁴³Hospital Universitario de Navarra, Pamplona, Spain, ⁴⁴Hospital Universitario de Cabueñes, Gijón, Spain, ⁴⁵Hospital Universitario Infanta Elena, Valdemoro, Madrid, Spain, ⁴⁶Hospital Universitario Marques de Valdecilla, Immunopathology group, IDIVAL, Santander, Cantabria, Spain, ⁴⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁴⁸Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain, ⁴⁹Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Spain, ⁵⁰Hospital Universitario Infanta Sofía, Madrid, Spain, ⁵¹HUP La Fe, Valencia, Spain, ⁵²Hospital Infanta Cristina, Parla, Spain, ⁵³Hospital General de Villalba, Collado Villalba, Spain
Background/Purpose: Anifrolumab (ANI) is a human monoclonal antibody that binds to the type I interferon receptor subunit 1 (IFNAR1), thus blocking the biological activity of…
Abstract Number: 1687 • ACR Convergence 2024
IgG and IgA anti-LIN28A Outperform Anti-dsDNA and anti-Sm in Distinguishing SLE from Health and Other Autoimmune Diseases
Ioannis Parodis¹, Dionysis Nikolopoulos², Julius Lindblom³, Denis Lagutkin³, Lorenzo Beretta⁴, Maria Orietta Borghi⁵, Janique Peyper⁶, Guillermo Barturen⁷, Per-Johan Jakobsson³, Marta Alarcon-Riquelme⁸, Natalia Sherina³ and Helena Idborg⁹, and PRECISESADS Clinical Consortium, ¹Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ³Karolinska Institutet, Stockholm, Sweden, ⁴Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, ⁵Università degli Studi di Milano Statale, Milano, Italy, ⁶Sengenics Corporation Pte Ltd, Singapore, Singapore, ⁷Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ⁸Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁹Karolinska Institutet, Solna, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is characterised by the production of a multitude of autoantibodies (abs). The diagnosis of SLE is supported by the presence…
Abstract Number: 1770 • ACR Convergence 2024
Assessing S100A4 and Myofibroblast Phenotypes in the Pathogenesis of Cardiac and Cutaneous Neonatal Lupus
Nalani Sachan¹, Christina Firl², Philip Carlucci³, Nicola Fraser², Robert Clancy⁴ and Jill Buyon⁵, ¹NYU Grossman School of Medicine, New York, NY, ²NYU Langone Health, New York, NY, ³New York University School of Medicine, New York, NY, ⁴Columbia University Medical Center, New York, NY, ⁵New York University Grossman School of Medicine, New York, NY
Background/Purpose: Neonatal lupus (NL), driven by fetal exposure to maternal anti-SSA/Ro autoantibodies, typically results in permanent cardiac manifestations in utero and/or a transient rash postnatally.…
Abstract Number: 1799 • ACR Convergence 2024
In VitroEvidence for the Restoration of Glucocorticoid Sensitivity by Toll-Like Receptor 7 and 8 Inhibition in Systemic Lupus Erythematosus
Jia Xin Chow¹, Rochelle Sherlock², Taylah Bennett², Eric Morand³ and Sarah Jones², ¹Monash University, Melbourne, Victoria, Australia, ²Monash University, Melbourne, Australia, ³School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: The strategy of inhibiting toll-like receptors (TLR) 7 and 8 is being evaluated in clinical trials in systemic lupus erythematosus (SLE) to assess its…
Abstract Number: 1876 • ACR Convergence 2024
Automated Case Identification of Patients with End-Stage Renal Disease and Systemic Lupus Erythematosus Using Machine Learning
Mario Felix¹ and Lais Osmani², ¹Yale, Hamden, CT, ²Yale, New Haven, CT
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease, with 4-28% of patients developing End-Stage Renal Disease (ESRD). Accurate identification of these patients is…
Abstract Number: 2170 • ACR Convergence 2024
Preliminary Evaluation of a Patient-Reported Version for the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): The Systemic Lupus Erythematosus Disease Activity Questionnaire (SLEDAQ)
Patti Katz¹, Amanda Eudy², Sarah Patterson³, Jennifer Rogers⁴, David Pisetsky⁵, Megan Clowse⁶ and Maria Dall'Era⁷, ¹UCSF, San Rafael, CA, ²Duke University, Raleigh, NC, ³University of California San Francisco, San Francisco, CA, ⁴Duke University, Durham, ⁵Duke University Medical Center, Durham, NC, ⁶Duke University, Chapel Hill, NC, ⁷UCSF, Corte Madera, CA
Background/Purpose: Much of the evidence demonstrating the impact of systemic lupus erythematosus (SLE) on patients’ lives, functioning, and quality of life has come from observational…
Abstract Number: 2383 • ACR Convergence 2024
Outcomes of Systemic Lupus Erythematosus Hospitalizations: Insights from a Multinational Tertiary Center Experience
Miral Gharib¹, Karima Becetti¹, Hana J.Abukhadijah², Fiaz Alam¹, Aishwariya Padmakumari³, Mohamed Awni AlKahlout³, rawan sheikh saleh¹, Muhammad Bilal Jamshaid⁴ and Samar Alemadi⁵, ¹hamad medical corporation, Doha, Qatar, ²Hamad medical corporation, doha, Ad Dawhah, Qatar, ³HMC, Doha, Qatar, ⁴Hamad Corp - Hamad General Hospital, Al sadd, Qatar, ⁵Hamad medical corporation, Doha, Qatar
Background/Purpose: Systemic Lupus Erythematosus is characterized by diverse clinical presentations and a remarkably unpredictable course. Although survival rate has increased in recent decades, morbidity and…
Abstract Number: 2402 • ACR Convergence 2024
Belimumab Reduces Disease Flares versus Placebo in Adults with Early Active Systemic Lupus Erythematosus: Results of a Large Integrated Analysis
Marta Mosca¹, Karen Costenbader², Joan Merrill³, Holly Quasny⁴, Christine Henning⁵, Steven Bloom⁶, Julia Harris⁶, Ciara O’Shea⁷, Tatsuya Atsumi⁸ and Ronald Van Vollenhoven⁹, ¹University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ²Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ³Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, ⁴GSK, Clinical Sciences, Durham, NC, ⁵GSK, Global Medical Affairs, Durham, NC, ⁶GSK, Immunology Biostatistics, Brentford, United Kingdom, ⁷GSK, Rheumatology, Global Medical Affairs, Dublin, Ireland, ⁸Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ⁹Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: SLE flares are associated with increased risk of organ damage/mortality; flare prevention is a key treatment goal.1 Initiating treatment earlier has benefits in autoimmune…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].